The American journal of gastroenterology · 2021
Rates and Predictors of Undergoing Different Hepatocellular Carcinoma Screening Tests in Patients With Cirrhosis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Nicole J, Jacob David A, Ioannou George N, John Binu V, Rogal Shari, Rozenberg-Ben-Dror Karine
Аннотация
INTRODUCTION: We aimed to assess rates and predictors of hepatocellular carcinoma (HCC) screening among patients with cirrhosis.
METHODS: We reviewed electronic health records of 11,361 patients with cirrhosis from 11 U.S. Veterans Health Administration facilities for receipt of HCC screening in the 6 months preceding October 1, 2019.
RESULTS: Nearly half of the cohort (46%) received HCC screening over a 6-month period. Screening rates and modalities (ultrasound, computed tomography, magnetic resonance imaging, serum alpha fetoprotein) varied by facility. Screening was associated with race/ethnicity, body mass index ≥ 25, cirrhosis etiology, thrombocytopenia, Fibrosis-4 ≥ 3.25, and lower Model for End-Stage Liver Disease-Sodium.
DISCUSSION: HCC screening rates varied by facility. Higher risk patients were more likely to receive screening.
METHODS: We reviewed electronic health records of 11,361 patients with cirrhosis from 11 U.S. Veterans Health Administration facilities for receipt of HCC screening in the 6 months preceding October 1, 2019.
RESULTS: Nearly half of the cohort (46%) received HCC screening over a 6-month period. Screening rates and modalities (ultrasound, computed tomography, magnetic resonance imaging, serum alpha fetoprotein) varied by facility. Screening was associated with race/ethnicity, body mass index ≥ 25, cirrhosis etiology, thrombocytopenia, Fibrosis-4 ≥ 3.25, and lower Model for End-Stage Liver Disease-Sodium.
DISCUSSION: HCC screening rates varied by facility. Higher risk patients were more likely to receive screening.
Предметные рубрики MeSH
AdultAgedAlanine TransaminaseAspartate AminotransferasesBiomarkers, TumorCarcinoma, HepatocellularEarly Detection of CancerEnd Stage Liver DiseaseEthnicityFemaleGuideline AdherenceHispanic or LatinoHumansLiver CirrhosisLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedMultivariate AnalysisOverweightPractice Guidelines as TopicSeverity of Illness IndexThrombocytopeniaTomography, X-Ray ComputedUltrasonographyUnited StatesUnited States Department of Veterans Affairsalpha-Fetoproteins